Initiate Basal Insulin Immediately
For a patient with HbA1c of 9.2% who cannot tolerate GLP-1 receptor agonists, you should initiate basal insulin therapy as the next treatment step. This represents a significantly elevated A1C requiring prompt, effective glucose-lowering intervention 1.
Why Basal Insulin is the Appropriate Choice
With an A1C of 9.2%, this patient needs a therapy with robust glucose-lowering efficacy. Since GLP-1 receptor agonists are not tolerated, basal insulin becomes the preferred injectable option. The 2025 ADA Standards of Care explicitly state that when injectable therapy is needed and GLP-1 RAs are "not appropriate," basal insulin should be initiated 1.
The A1C reduction needed here (approximately 2% to reach most individualized goals) requires the potency that insulin provides - typically 1.5-2.5% reduction depending on starting values and titration 1.
Specific Initiation Protocol
Start with the following approach 1:
- Initial dose: 10 units per day OR 0.1-0.2 units/kg per day of basal insulin analog or bedtime NPH
- Set a fasting plasma glucose goal based on individualized targets (typically 80-130 mg/dL for most patients)
- Titration algorithm: Increase by 2 units every 3 days until FPG goal is reached without hypoglycemia
- For hypoglycemia: Identify the cause; if unclear, reduce dose by 10-20%
Choice of Basal Insulin
Select between:
- Long-acting basal insulin analogs (preferred for lower hypoglycemia risk)
- NPH insulin (bedtime dosing, more cost-effective option)
The choice should be based on person-specific considerations, including cost and hypoglycemia risk 1. Basal analogs offer more predictable pharmacokinetics with lower nocturnal hypoglycemia risk compared to NPH.
Critical Considerations Before Starting
Ensure Metformin is Optimized
If not already on metformin (and no contraindications exist), this should be the foundation of therapy 1.
Consider SGLT2 Inhibitors
Before or concurrent with insulin initiation, strongly consider adding an SGLT2 inhibitor if the patient has:
- Established cardiovascular disease
- Heart failure
- Chronic kidney disease (eGFR >20 mL/min/1.73 m²)
These provide cardiovascular and renal protection independent of A1C lowering 1. The 2025 guidelines emphasize that SGLT2 inhibitors are recommended for these comorbidities regardless of glycemic control.
What NOT to Do
Do not delay treatment intensification - therapeutic inertia at this A1C level (9.2%) increases risk of complications 1. The guidelines explicitly state that treatment intensification should not be delayed for patients not meeting goals.
Do not add a DPP-4 inhibitor as an alternative to GLP-1 RAs - while both are incretin-based, DPP-4 inhibitors provide only modest A1C reduction (0.5-0.8%) which is insufficient for this degree of hyperglycemia 1.
Monitoring and Follow-up
- Reassess every 3-6 months to avoid therapeutic inertia 1
- Prescribe glucagon for emergent hypoglycemia 1
- Provide diabetes self-management education on insulin administration, glucose monitoring, and hypoglycemia recognition/treatment
- Monitor for signs of overbasalization: elevated bedtime-to-morning glucose differential, hypoglycemia, or high glucose variability 1
If A1C Remains Above Goal on Basal Insulin
Should the patient not reach target on optimized basal insulin alone, the next step is adding prandial insulin, starting with one dose at the largest meal (typically 4 units or 10% of basal dose) 1. However, this decision comes after adequate basal insulin titration - don't advance prematurely.
Common Pitfall to Avoid
The most critical error would be choosing a less potent oral agent (like a DPP-4 inhibitor or sulfonylurea alone) when this A1C level demands more aggressive intervention. At 9.2%, oral agents added to metformin will likely be insufficient - each oral class typically reduces A1C by only 0.7-1.0% 1.